期刊
ALZHEIMERS & DEMENTIA
卷 10, 期 6, 页码 760-768出版社
WILEY
DOI: 10.1016/j.jalz.2014.02.008
关键词
Cross-cultural comparison; Neuropsychological tests; Alzheimer's disease; Primary prevention delay of onset of MCI due to Alzheimer's disease
资金
- Zinfandel Pharmaceuticals, Durham, NC
- Takeda Pharmaceuticals, Deerfield, IL
- National Institute on Aging [K01-AG029336, P30-AG028377]
- MURDOCK Study and Duke University's CTSA grant from the National Center for Advancing Translational Sciences (NCATS) [UL1-RR024128-01]
Background: Understanding regional differences in cognitive performance is important for interpretation of data from large multinational clinical trials. Methods: Data from Durham and Cabarrus Counties in North Carolina, USA and Tomsk, Russia (n = 2972) were evaluated. The Montreal Cognitive Assessment (MoCA), Trail Making Test Part B (Trails B), Consortium to Establish a Registry for Alzheimer's Disease Word List Memory Test (WLM) delayed recall, and self-report Alzheimer's Disease Cooperative Studies Mail-In Cognitive Function Screening Instrument (MCFSI) were administered at each site. Multilevel modeling measured the variance explained by site and predictors of cognitive performance. Results: Site differences accounted for 11% of the variation in the MoCA, 1.6% in Trails B, 1.7% in WLM, and 0.8% in MCFSI scores. Prior memory testing was significantly associated with WLM. Diabetes and stroke were significantly associated with Trails B and MCFSI. Conclusions: Sources of variation include cultural differences, health conditions, and exposure to test stimuli. Findings highlight the importance of local norms to interpret test performance. (C) 2014 The Alzheimer's Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据